

Declaration of Interests Register

Technology Appraisal Committee A

Publication Date: 23/09/2020

Topic: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma [ID1576]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Kate Cwynarski	Clinical Expert	Direct financial	Has done paid consultancy, advisory and speaker work for Roche, and received travel support from Roche to attend conferences.		January 2020		Interests declared and participated in part 1 of the meetings. Agreed by Chair Dr Jane Adam.
Sridhar Chaganti	Clinical Expert	Direct financial	Received honoraria for advisory boards for Roche.		January 2020		Interest declared and participated in part 1 of the meetings. Agreed by Chair Dr Jane Adam.